Therapeutic approaches in metastatic renal cell carcinoma: Local immunotherapy

Urologe - Ausgabe A

Volumn 43, Issue SUPPL. 2, 2004, Pages

  Huland, Edith ^a   Heinzer, H ^a   Jorres R A ^b   Loppow, D ^b   Huland, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

AEROSOL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSPNEA; FORCED EXPIRATORY VOLUME; HIGH RISK PATIENT; HOARSENESS; HUMAN; INHALER; KIDNEY CARCINOMA; KIDNEY METASTASIS; LABORATORY TEST; LUNG FUNCTION; LUNG METASTASIS; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CONTROLLED CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 4744363273     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-004-0606-6     Document Type: Conference Paper

References (18)

1. Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310-7313
2. Cotran RS, Pober JS, Gimbrone MA, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT (1988) Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 140:1883-1888
3. Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, Oskam R, Franks CR (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Annals Oncol 3:475-480
4. Huland E, Burger A, Fleischer J, Fornara P, Hatzmann E, Heidenreich A, Heinzer H, Heynemann H, Hoffmann L, Hofmann R, Huland H, Kämpfer I, Kindler M, Kirchner H, Mehlhorn G, Moniak Th, Rebmann U, Roigas J, Schneider Th, Schnorr D, Schmitz H-J, Wenisch R, Varga Z, Vinke J (2003) Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. Folia Biol 49:183-190
5. Loppow D, Huland E, Heinzer H, Grönke L, Gercken G, Magnussen H, Jörres RA (2004) Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation. Resp Med (in press)
6. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer. J Clin Oncol 21:3127-3132
7. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679
8. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928-1935
9. Motzer RJ, Mazumdar M, Bacik J (1999) Survival and Prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17:2530-2540
10. Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A:1310-1314
11. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198-1220
12. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375
13. Clark JI, Gaynor ER, Martone B Budds SC, Manjunath R, Waters WB, Sosman JA (1999) Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. Clin Cancer Res 5:2374-2380
14. Heinzer H, Mir TS, Huland E, Huland H (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 17:3612-3620
15. http://www.emea.eu.int/pdfs/human/comp/opinion/122803en.pdf. Cited on 18.8.2003
16. Lorenz J, Wilhelm K, Kessler M, et al (1996) Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy:toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 2:1115-1122
17. Zissel G, Aulitzky WE, Lorenz J, Huber C, Müller-Quernheim J (1996) Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol Immunother 42:122-126
18. Gaede KI, Zissel G, Schwulera U, Struff WG, Lorenz J, Aulitzky WE, Zipfel P, Schrum S, Schlaak M, Huber C, Müller-Quernheim J (1997) Spontaneous and interleukin-2-modulated cytokine release by bronchoalveolar cells in pulmonary malignancy. Eur Cytokine Netw 8:395-400